Keyphrases
Glioblastoma
100%
Neuro-oncology
44%
Tumor
40%
Brain Metastases
36%
Glioma
30%
Recurrent Glioblastoma
26%
High-grade Glioma
24%
Tumor Treating Fields
22%
Indoleamine 2,3-dioxygenase 1 (IDO1)
21%
Meningioma
21%
Leptomeningeal Metastasis
20%
Central Nervous System
20%
Primary Central Nervous System Lymphoma (PCNSL)
20%
Malignant Glioma
19%
Bevacizumab
18%
Neurology
17%
CNS Metastases
17%
Central Nervous System Tumors
16%
Systemic Therapy
16%
Brain Tumor
16%
Medical Students
15%
Clinical Trials
15%
Radiotherapy
14%
Neurologist
14%
Non-small Cell Lung Cancer (NSCLC)
14%
Clinical Management
13%
Objective Structured Clinical Examination
13%
Temozolomide
13%
Cerebrospinal Fluid
13%
Overall Survival
13%
Anti-PD-1 Immunotherapy
12%
Von Hippel-Lindau Disease
12%
Multi-institutional
12%
Solid Tumors
12%
Newly Diagnosed
12%
Neuroscience
12%
Pleomorphic Xanthoastrocytoma
11%
Targeted Therapy
11%
Median Overall Survival
11%
Lung Cancer Brain Metastases
11%
Primary Brain Tumor
11%
Gene Therapy
10%
Clinical Practice
10%
Patient Care
10%
Leptomeningeal Carcinomatosis
10%
Neurology Clerkship
10%
Epilepsy
9%
Hemangioblastoma
9%
American Society of Clinical Oncology
9%
Interleukin-12 (IL-12)
9%
Medicine and Dentistry
Glioblastoma
85%
Neoplasm
64%
Neuro-Oncology
41%
Ganglioglioma
40%
Intracranial Tumor
31%
Brain Metastasis
30%
Diseases
29%
Neurology
28%
Radiation Therapy
23%
Immunotherapy
23%
Metastatic Carcinoma
23%
Central Nervous System
22%
Meningioma
22%
Malignant Neoplasm
18%
Clinical Trial
17%
Overall Survival
17%
Tumor Treating Fields
16%
Primary Central Nervous System Lymphoma
15%
Medical Student
14%
Central Nervous System Metastasis
13%
Systematic Review
13%
Clinical Management
13%
Central Nervous System Tumor
12%
Epileptic Seizure
12%
Clinical Oncology
12%
Clinical Examination
12%
Hemangioblastoma
11%
Systemic Therapy
11%
Meningeal Carcinomatosis
11%
Bevacizumab
10%
Outpatient
10%
Pathophysiology
10%
Medicine
10%
Temozolomide
10%
Progression Free Survival
10%
Indoleamine 2,3 Dioxygenase
10%
Targeted Therapy
9%
Von Hippel-Lindau Disease
9%
Pleomorphic Xanthoastrocytoma
9%
Solid Malignant Neoplasm
9%
Therapeutic Management
9%
Magnetic Resonance Imaging
9%
Immunoglobulin
8%
Combination Therapy
8%
Cancer
8%
Immunosuppressive Drug
8%
Non Small Cell Lung Cancer
7%
Breast Cancer
7%
Phase II Trials
7%
Nervous System
7%